Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features

Muniesa, Cristina; Estrach, M.T.; Gallardo, Fernando; García-Muret, M. Pilar; Climent, Fina; Salar, Antonio; Servitje, Octavio

doi:10.1016/j.jaad.2011.03.031

Cited by 23 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 Recommended staging is the same as that for other forms of aggressive NHL (positron emission tomography-computed tomography, bone marrow biopsy) with the addition of specific CNS staging with lumbar puncture for cerebrospinal fluid analysis by cytology and flow cytometry (since there is evidence to support improved sensitivity 29 ) and brain magnetic resonance imaging. We recommend thorough examination of the skin because cutaneous DLBCL (leg type) and testicular DLBCL have been concurrently reported, 30 and the skin is a potential site of extranodal recurrence. HIV serology should be performed.…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

Primary testicular lymphoma

Cheah

Wirth

Seymour

2014

Blood

178

174

View full text Add to dashboard Cite

Primary testicular lymphoma (PTL) is a rare, clinically aggressive form of extranodal lymphoma. The vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are clinically important and must be recognized. In this review, we discuss the incidence, clinical presentation, and prognostic factors of PTL and present a summary of the recent advances in our understanding of its pathophysiology, which may account for the characteristic clinical features. Although outcomes for patients with PTL have historically been poor, significant gains have been made with the successive addition of radiotherapy (RT), full-course anthracycline-based chemotherapy, rituximab and central nervous system–directed prophylaxis. We describe the larger retrospective series and prospective clinical trials and critically examine the role of RT. Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 21 days with intrathecal methotrexate and locoregional RT is the current international standard of care, a substantial minority of patients progress, representing an unmet medical need. Finally, we discuss new treatment approaches and recent discoveries that may translate into improved outcomes for patients with PTL.

show abstract

Section: Diagnosis and Stagingmentioning

confidence: 99%

Primary testicular lymphoma

Cheah

Wirth

Seymour

2014

Blood

178

174

View full text Add to dashboard Cite

show abstract

“…5,6 In addition to traditional B-cell markers (CD19, CD20, CD22, CD79a, PAX-5), PCDLBCL-LT classically expresses BCL2, IRF4/MUM-1, and FOXP1 (Figure 1, D through F). However, this immunophenotype is not specific to PCDLBCL-LT and may also be seen in other diffuse large B-cell lymphomas that secondarily involve the skin, 6,12 or in uncommon cases of PCFCL. 9,10 Moreover, its importance to establishing the diagnosis of PCDLBCL-LT is controversial.…”

mentioning

confidence: 97%

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Diagnostic Considerations

Hristov

2012

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—Primary cutaneous diffuse large B-cell lymphoma, leg type, may show features that overlap with other lymphomas. However, timely recognition of this entity can have important clinical and therapeutic implications. Objective.—To review the clinical, morphologic, and immunophenotypic characteristics of primary cutaneous diffuse large B-cell lymphoma, leg type, and juxtapose these features with other diagnostic considerations. In particular, other variants of primary cutaneous diffuse large B-cell lymphoma, as well as primary cutaneous follicle center lymphoma, will be reviewed. Additionally, systemic/extracutaneous lymphomas will be discussed, including diffuse large B-cell lymphoma, not otherwise specified, Epstein-Barr virus–positive diffuse large B-cell lymphoma of the elderly, and lymphomatoid granulomatosis. Data Sources.—Relevant literature will be reviewed and key differentiating findings will be highlighted. Conclusions.—Although primary cutaneous diffuse large B-cell lymphoma, leg type, may show aspects that overlap with other lymphomas, it can be distinguished from other entities in the differential diagnosis.

show abstract

“…4 At the time of diagnosis, the tumors are often larger than other B-cell lymphoma subtypes with a tendency for involvement of the subcutaneous tissue and ulceration of the epidermis. 4 At the time of diagnosis, the tumors are often larger than other B-cell lymphoma subtypes with a tendency for involvement of the subcutaneous tissue and ulceration of the epidermis.…”

Section: Discussionmentioning

confidence: 99%

“…4 At the time of diagnosis, the tumors are often larger than other B-cell lymphoma subtypes with a tendency for involvement of the subcutaneous tissue and ulceration of the epidermis. 4 This lymphoma affects predominantly elderly patients, especially women, with a male-to-female ratio of approximately 1:2. 5 Primary cutaneous diffuse large B-cell lymphoma, leg type, is characterized by a high proliferation rate and a tendency for dissemination to extracutaneous sitesVmost frequently the regional lymph nodes and the central nervous system.…”

Section: Discussionmentioning

confidence: 99%